Morgan Joseph reiterates a 'Buy' rating on BioMarin Pharmaceutical (Nasdaq: BMRN), price target $20.

Morgan analyst says, "Although the possibility ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE